Samples from patients with AML with erythroid or megakaryocytic differentiation are highly sensitive to BCL-XL inhibition ex vivo. (A) Ex vivo DSS of A-1331852, venetoclax, and navitoclax in samples from patients with AML (n = 21) and healthy BM samples (n = 2). AML cases with TP53 mutation are colored red. P values were calculated using a Wilcoxon rank-sum test. (B) Dose-response curves of samples with erythroid/megakaryoblastic features treated ex vivo with A-1331852. DSS, drug sensitivity score.